

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date: Tuesday, June 30, 2026
Time: 9:00 am Central Time
Location: Zoom Teleconference
Institution: Northwestern University, Chicago, IL
Principal Investigator: Farrah Mateen, MD, PhD
Protocol: Poseida Therapeutics, Inc., GN45773
NCT Number: NCT07008378
Meeting Type: Continuing Review of Protocol and Site
Title: A Phase I, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Patients with Multiple Sclerosis

1. Call to order:

The Meeting was called to order at 9:18 am Central Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Six voting members were present, including two local members unaffiliated with the institution and the Institution's Biosafety Officer. Also present were three Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

The Biosafety Officer confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 6 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair noted changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for P-CD19CD20- ALLO1 since it consists of primary human cells modified using a plasmid and mRNA. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of PCD19CD20-ALLO1 locally**, provided all other biosafety criteria for study closure are also met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 6 NO: 0 ABSTAIN: 0

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

1. The Committee recommended that Biosafety SOP Addendum Section 3.2.8 be revised to remove the reference to the Biological Safety Cabinet (BSC) since the study agent will be prepared on a countertop in the Dosing Room.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Biosafety Officer.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 6

NO: 0

ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 9:25 am Central Time.

15. Post-meeting notes: None.

Documents reviewed:

Agenda

Protocol, Version 3, dated 05-02-2025

Investigator's Brochure, Edition 5, dated 09-17-2025

Pharmacy and Cell Therapy Manual, Version 4, dated 11-17-2025

Research Modification Evaluation, Investigator's Brochure, Edition 5

Research Modification Evaluation, Pharmacy and Cell Therapy Manual, Version 3

Research Modification Evaluation, Pharmacy and Cell Therapy Manual, Version, 4

Biological Risk Assessment and Summary, updated 05-07-2026

Site Map, Olson, 1st Floor, dated 01-23-2026

Site Map, Olson, 7th Floor, MCCT, Room 7-424, dated 02-27-2025

Site Map, Olson, 7th Floor, MCCT, Room 7-613, dated 02-19-2024

Site Map, Prentice, 16th Floor, dated 04-12-2024

Site Map, Feinberg and Olson Loading Docks, received 10-16-2018

Site Inspection Checklist, Cell Therapies, expires 03-05-2027, updated 06-17-2026

Photos, Prentice Hospital, dated 04-25-2025

Photos, Olson Pavilion, MCCT, dated 06-05-2025

Photos, Olson Pavilion, Dosing, dated 05-01-2025

Photos, Feinberg and Olson Loading Dock, dated 03-25-2026

Biohazard Sign, Olson MCCT, dated 06-17-2026

Biohazard Sign, Dosing Areas, dated 06-17-2026

SOP, Biosafety for Genetically Modified Human Cells, dated 06-15-2026

SOP, Addendum Biosafety for Allogeneic Cells, dated 02-03-2026

Training, Shipping Certification, expires 06-05-2027

CRRF, dated 04-14-2026

Prior Meeting Minutes, Initial, dated 07-28-2025